Alpha 2.0
Login Register
» Authors » Charles Schweizer

Charles Schweizer

Explore the profile of Charles Schweizer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 407
Followers 0
Related Specialties
Oncology
Genetics
Pharmacology
Top 10 Co-Authors
Susan C Weil
Wenquan Wang
Luigi Grasso
Elizabeth B Somers
Daniel J OShannessy
Susan Weil
Nicholas C Nicolaides
Raffit Hassan
Ira Pastan
Shawn Fernando
Published In
Clin Cancer Res
Lung Cancer
Gynecol Oncol
Oncotarget
Cancer Biol Ther
Affiliations
Soon will be listed here.
Recent Articles
1.
Farletuzumab, a monoclonal antibody directed against folate receptor alpha, shows no evidence of teratogenicity in cynomolgus monkeys
Moriyama T, Kakiuchi D, Grasso L, Hutto D, Fernando D, Schweizer C
Reprod Toxicol . 2018 Jun; 79:89-95. PMID: 29928988
Farletuzumab is a humanized monoclonal antibody targeting human folate receptor alpha, which is being developed as an anti-cancer drug. A non-human primate reproductive study was conducted to evaluate whether it...
2.
CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients
Nicolaides N, Schweizer C, Somers E, Wang W, Fernando S, Ross E, et al.
Cancer Biol Ther . 2018 Apr; 19(7):622-630. PMID: 29652548
The tumor-shed antigen CA125 has recently been found to bind certain monoclonal antibodies (mAbs) and suppress immune-effector mediated killing through perturbation of the Fc domain with CD16a and CD32a Fc-γ ...
3.
A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma
DAngelo S, Hamid O, Tarhini A, Schadendorf D, Chmielowski B, Collichio F, et al.
Invest New Drugs . 2017 Nov; 36(1):103-113. PMID: 29127533
Objectives Ontuxizumab (MORAB-004) is a first-in-class monoclonal antibody that interferes with endosialin function, which is important in tumor stromal cell function, angiogenesis, and tumor growth. This Phase 2 study evaluated...
4.
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer
Grothey A, Strosberg J, Renfro L, Hurwitz H, Marshall J, Safran H, et al.
Clin Cancer Res . 2017 Nov; 24(2):316-325. PMID: 29084918
The purpose of this study was to evaluate the safety and efficacy of ontuxizumab (MORAb-004), a monoclonal antibody that interferes with endosialin (tumor endothelial marker-1) function, in patients with chemorefractory...
5.
FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125
Wang W, Somers E, Ross E, Kline J, OShannessy D, Schweizer C, et al.
Cytogenet Genome Res . 2017 Oct; 152(4):169-179. PMID: 29041009
Farletuzumab is a humanized monoclonal antibody that binds to folate receptor alpha and elicits an anti-tumor response via immune effector activity. Recent studies from a global phase 3 trial in...
6.
Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement
Kline J, Kennedy R, Albone E, Chao Q, Fernando S, McDonough J, et al.
Oncotarget . 2017 Sep; 8(32):52045-52060. PMID: 28881712
Cancers employ a number of mechanisms to evade host immune responses. Here we report the effects of tumor-shed antigen CA125/MUC16 on suppressing IgG1-mediated antibody-dependent cellular cytotoxicity (ADCC). This evidence stems...
7.
Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer
OShannessy D, Bendas K, Schweizer C, Wang W, Albone E, Somers E, et al.
Genomics . 2017 Apr; 109(3-4):251-257. PMID: 28450240
Farletuzumab (FAR) is a humanized monoclonal antibody (mAb) that binds to folate receptor alpha. A Ph3 trial in ovarian cancer patients treated with carboplatin/taxane plus FAR or placebo did not...
8.
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse
Vergote I, Armstrong D, Scambia G, Teneriello M, Sehouli J, Schweizer C, et al.
J Clin Oncol . 2016 Mar; 34(19):2271-8. PMID: 27001568
Purpose: Farletuzumab is a humanized monoclonal antibody that binds to folate receptor-α, which is highly expressed in ovarian carcinoma and largely absent from normal tissue. Farletuzumab was investigated in a...
9.
Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer
Kim K, Jelovac D, Armstrong D, Schwartz B, Weil S, Schweizer C, et al.
Gynecol Oncol . 2015 Dec; 140(2):210-4. PMID: 26644263
Objective: Farletuzumab is a humanized monoclonal antibody that binds to folate receptor alpha, over-expressed in epithelial ovarian cancer (EOC) but largely absent in normal tissue. Previously, carboplatin plus pegylated liposomal...
10.
Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer
Farrell C, Schweizer C, Wustner J, Weil S, Namiki M, Nakano T, et al.
Cancer Chemother Pharmacol . 2012 Sep; 70(5):727-34. PMID: 22955257
Purpose: The purpose of this analysis was to develop a population pharmacokinetic model for farletuzumab, a humanized immunoglobulin (Ig)G(1) monoclonal antibody (mAb) to the folate receptor alpha, which is a...